<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03360396</url>
  </required_header>
  <id_info>
    <org_study_id>BTG-004517-01</org_study_id>
    <nct_id>NCT03360396</nct_id>
  </id_info>
  <brief_title>Study of PneumRx Endobronchial Coil System in Treatment of Subjects With Severe Emphysema</brief_title>
  <acronym>ELEVATE</acronym>
  <official_title>A Randomized Controlled Study of PneumRx Endobronchial Coil System Versus Standard-of-Care Medical Management in the Treatment of Subjects With Severe Emphysema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PneumRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PneumRx, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at outcomes between Endobronchial Coil Treatment and Control groups in
      patients with severe heterogeneous and or homogeneous emphysema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, multicenter, randomized, controlled study comparing outcomes
      between the Endobronchial Coil and Control Groups. Subjects will be block randomized in a
      Treatment to Control ratio of 2:1. The randomization will be stratified by site and
      homogeneous versus heterogeneous emphysema, to support a balance of patients with differing
      heterogeneity in both the Treatment and Control Groups
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change in FEV1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SGRQ</measure>
    <time_frame>6 months</time_frame>
    <description>Change in SGRQ score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder Rate</measure>
    <time_frame>6 months</time_frame>
    <description>percent change in subjects who achieve two or more MCIDs (6MWT &gt;=26 meters, SGRQ &lt;= -4 points, RV &gt;=350 ml, FEV1 &gt;=10%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Expiratory Lobar Volume</measure>
    <time_frame>6 months</time_frame>
    <description>change in mean expiratory lobar volume of treated lobes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VC</measure>
    <time_frame>6 months</time_frame>
    <description>Change in vital capacity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pulmonary Function - RV</measure>
    <time_frame>6 months</time_frame>
    <description>RV</description>
  </other_outcome>
  <other_outcome>
    <measure>Pulmonary Function - RV/TLC</measure>
    <time_frame>6 months</time_frame>
    <description>RV/TLC</description>
  </other_outcome>
  <other_outcome>
    <measure>Pulmonary Function - FEV`</measure>
    <time_frame>6 months</time_frame>
    <description>FEV1</description>
  </other_outcome>
  <other_outcome>
    <measure>Pulmonary Function FEV1/FVC</measure>
    <time_frame>6 months</time_frame>
    <description>FEV1/FVC</description>
  </other_outcome>
  <other_outcome>
    <measure>6MWT</measure>
    <time_frame>6 months</time_frame>
    <description>change in exercise capacity (6MWT)</description>
  </other_outcome>
  <other_outcome>
    <measure>CAT</measure>
    <time_frame>6 months</time_frame>
    <description>change in CAT</description>
  </other_outcome>
  <other_outcome>
    <measure>EQ-5D</measure>
    <time_frame>6 months</time_frame>
    <description>change in EQ-5D</description>
  </other_outcome>
  <other_outcome>
    <measure>Individual MCID responder rates 6MWT</measure>
    <time_frame>6 months</time_frame>
    <description>6MWT</description>
  </other_outcome>
  <other_outcome>
    <measure>Individual MCID responder rates FEV1</measure>
    <time_frame>6 months</time_frame>
    <description>FEV1</description>
  </other_outcome>
  <other_outcome>
    <measure>Individual MCID responder rates SGRQ</measure>
    <time_frame>6 months</time_frame>
    <description>SGRQ</description>
  </other_outcome>
  <other_outcome>
    <measure>responder rate of FEV1</measure>
    <time_frame>6 months</time_frame>
    <description>responder rate defined as percent of subjects who achieve FEV1 change &gt;= 12%</description>
  </other_outcome>
  <other_outcome>
    <measure>SGRQ responder rate</measure>
    <time_frame>6 months</time_frame>
    <description>responder rate defined as percent of subjects that achieve SGRQ &lt;= -8 points</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Emphysema</condition>
  <arm_group>
    <arm_group_label>Endobronchial Coils</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endobronchial Coils</intervention_name>
    <description>Endobronchial Coil implants</description>
    <arm_group_label>Endobronchial Coils</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Read, understood and signed the Informed Consent form

          -  Meets indications for use per the IFU

          -  Bilateral heterogeneous and/or homogeneous emphysema

          -  Post bronchodilator 15% predicted ≤ Forced Expiratory Volume in 1 second (FEV1) ≤ 45%
             predicted

          -  Post bronchodilator Residual Volume (RV) ≥ 200% predicted

          -  Post bronchodilator Total Lung Capacity (TLC) &gt;100% pred.

          -  Post bronchodilator RV/TLC &gt; 55%

          -  Dyspnea related to hyperinflation scored ≥ 2 on modified Medical Research Council
             (mMRC) dyspnea scale despite optimal medical management

          -  Receiving optimal drug therapy and medical management according to clinical practice.

          -  Performing regular physical activity, at least 2 times per week

          -  Stopped smoking as confirmed by carboxyhemoglobin (CoHB)

          -  100m ≤ 6 minute walk distance (6MWD) ≤ 450m

          -  Deemed eligible per Eligibility Review Committee (ERC)

        Exclusion Criteria:

          -  Meets any of the contraindications listed in the IFU

          -  Primary diagnosis of asthma

          -  Two (2) or more COPD exacerbations in the prior year, or 1 or more COPD exacerbations
             in the prior 3 months with indication for hospitalization assessment, according to
             GOLD 2017 recommendations .

          -  Predominant small airways disease defined as significant bronchiectasis with sputum
             production (&gt; 2 tablespoons daily) or significant bronchial wall thickening per High
             Resolution Computed Tomography (HRCT)

          -  Percent Low Attenuation Area (%LAA) &lt; 20% in the most damaged lobe of either lung.

          -  Computed Tomography (CT) Imaging consistent with active pulmonary infection,
             significant interstitial disease or pleural disease (predominant bulla &gt; 8cm or 1/3
             hemithorax), or severe bullous or predominant paraseptal emphysema pattern

          -  Lung pathology of nodule not proven stable or benign

          -  Radiographic confirmation of atelectasis or other scarring/fibrosis in areas of
             intended Coil implant

          -  Use of more than 10 mg/day prednisolone or equivalent dosage of a different
             corticosteroid

          -  Severe pulmonary hypertension (Right Ventricular Systolic Pressure (RVSP) &gt; 50 mm Hg
             or other signs of Pulmonary Hypertension (PHT) with right ventricular dysfunction)

          -  Severe hypercapnia (PaCO2 &gt; 55 mmHg on room air) and/or severe hypoxemia (PaO2 &lt; 45mm
             Hg on room air, High altitude criterion: PaO2 &lt; 30 mm Hg)

          -  Previous Lung Volume Reduction (LVR) surgery, lung transplantation, lobectomy, LVR
             devices or other device to treat COPD in either lung.

          -  Diagnosed with alpha-1 antitrypsin deficiency

          -  DLCO &lt; 20 %

          -  Significant, recent or unstable cardiac disease defined as severe heart failure (Left
             Ventricular Ejection Fraction (LVEF) &lt; 45% despite optimal medical management),
             unstable cardiac arrhythmia or coronary artery disease (angina on activity), or
             ischemic event in the past 6 months.

          -  Body Mass Index (BMI) &gt; 30
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felix Herth, MD,</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arschang Valipour, MD,FCCP,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Otto-Wagner-Spital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Otto-Wagner Spital</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arschang Valipour, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arschang Valipour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe Pison, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Pison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud Bourdin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arnaud Bourdin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nice</name>
      <address>
        <city>Nice</city>
        <zip>CS 51069</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Herve Mal, MD</last_name>
    </contact>
    <investigator>
      <last_name>Herve Mal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Reims - Hopital Maison Blanche</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Berlin - Medizinische Klinik mit Schwerpunkt Infektiologie und Pneumologie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralph-Harto Hubner, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ralph-Harto Hubner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftskrankenhaus Havelhöhe GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Grah, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christian Grah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinkum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhrlandklinik Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kaid Darwiche, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kaid Darwiche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachkliniken München-Gauting</name>
      <address>
        <city>Gauting</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wolfgang Geiserich, MD</last_name>
    </contact>
    <investigator>
      <last_name>Wolfgang Geiserich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans Klose, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungenklinik</name>
      <address>
        <city>Hemer</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha-Maria München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Fertl, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andreas Fertl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michela Bezzi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michela Bezzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>3150-3610536</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2017</study_first_submitted>
  <study_first_submitted_qc>November 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2017</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>severe heterogeneous emphysema</keyword>
  <keyword>severe homogeneous emphysema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

